In recent years, mathematical models have developed into an important tool for cancer research, combining quantitative analysis and natural processes. We have focused on Chronic Lymphocytic Leukemia (CLL), since it is one of the most common adult leukemias, which remains incurable. As the first step toward the mathematical prediction of in vivo drug efficacy, we first found that logistic growth best described the proliferation of fluorescently labeled murine A20 leukemic cells injected in immunocompetent Balb/c mice. Then, we tested the cytotoxic efficacy of Ibrutinib (Ibr) and Cytarabine (Cyt) in A20-bearing mice. The results afforded calculation of the killing rate of the A20 cells as a function of therapy. The experimental data were comp...
Abstract Immunotherapy has dramatically transformed the cancer treatment landscape largely due to th...
This study addresses a modified mathematical model of tumor growth with targeted chemotherapy consis...
Acute Lymphoblastic Leukemia (ALL) accounts for the 80% of leukemias when coming down to pediatric a...
Chlorambucil (Chl), Melphalan (Mel), and Cytarabine (Cyt) are recognized drugs used in the chemother...
AbstractWe propose and develop a pharmacokinetic model for the quantitative analysis of dose-time-ce...
The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is a new targeted therapy for patients with ch...
Chronic myeloid leukemia (CML) is a blood cancer characterized by dysregulated production of maturin...
B cell chronic lymphocytic leukemia (B-CLL) is known to have substantial clinical heterogeneity. The...
Doxorubicin treatment outcomes for non-Hodgkin’s lymphomas (NHL) are mathematically modelled and com...
Acute myeloid leukemia is a type of blood cancer characterized by an excessive build-up of immature ...
A mathematical model of the interaction between chronic lymphocytic leukemia (CLL) and CD4+ (helper)...
International audienceDoxorubicin treatment outcomes for non-Hodgkin's lymphomas (NHL) are mathemati...
The principles of mathematical modeling and analyses are applied to immunotherapy of human cancers. ...
© 2005 Nature Publishing GroupThe clinical success of the ABL tyrosine kinase inhibitor imatinib in ...
Immunotherapies for cancer are an emerging class of therapeutic strategies which aim to treat cancer...
Abstract Immunotherapy has dramatically transformed the cancer treatment landscape largely due to th...
This study addresses a modified mathematical model of tumor growth with targeted chemotherapy consis...
Acute Lymphoblastic Leukemia (ALL) accounts for the 80% of leukemias when coming down to pediatric a...
Chlorambucil (Chl), Melphalan (Mel), and Cytarabine (Cyt) are recognized drugs used in the chemother...
AbstractWe propose and develop a pharmacokinetic model for the quantitative analysis of dose-time-ce...
The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is a new targeted therapy for patients with ch...
Chronic myeloid leukemia (CML) is a blood cancer characterized by dysregulated production of maturin...
B cell chronic lymphocytic leukemia (B-CLL) is known to have substantial clinical heterogeneity. The...
Doxorubicin treatment outcomes for non-Hodgkin’s lymphomas (NHL) are mathematically modelled and com...
Acute myeloid leukemia is a type of blood cancer characterized by an excessive build-up of immature ...
A mathematical model of the interaction between chronic lymphocytic leukemia (CLL) and CD4+ (helper)...
International audienceDoxorubicin treatment outcomes for non-Hodgkin's lymphomas (NHL) are mathemati...
The principles of mathematical modeling and analyses are applied to immunotherapy of human cancers. ...
© 2005 Nature Publishing GroupThe clinical success of the ABL tyrosine kinase inhibitor imatinib in ...
Immunotherapies for cancer are an emerging class of therapeutic strategies which aim to treat cancer...
Abstract Immunotherapy has dramatically transformed the cancer treatment landscape largely due to th...
This study addresses a modified mathematical model of tumor growth with targeted chemotherapy consis...
Acute Lymphoblastic Leukemia (ALL) accounts for the 80% of leukemias when coming down to pediatric a...